The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial on cisplatin-doxorubicin hydrochloride-paclitaxel (TAP) combination as neoadjuvant chemotherapy (NACT) for locally advanced cervical adenocarcinoma (LACA).
Francesco Raspagliesi
Consultant or Advisory Role - Amgen
Stefano Ramondino
No relevant relationships to disclose
Flavia Zanaboni
Consultant or Advisory Role - Roche
Antonino Ditto
No relevant relationships to disclose
Eugenio Solima
No relevant relationships to disclose
Barbara Grijuela
No relevant relationships to disclose
Gian Battista Spatti
No relevant relationships to disclose
Massimo Gabbanini
No relevant relationships to disclose
Maria Mancini
No relevant relationships to disclose
Fabio Martinelli
No relevant relationships to disclose
Carla Amaya De Carrillo
No relevant relationships to disclose
Rosanna Fontanelli
No relevant relationships to disclose
Domenica Lorusso
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar